Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
An HBV-HIV Co-infected Patient Treated with Tenofovir-based Therapy who Achieved HBs Antigen/Antibody Seroconversion
Takao Watanabe, Yoshio Tokumoto, Masashi Hirooka, Yohei Koizumi, Fujimasa Tada, Hironori Ochi, Masanori Abe, Teru Kumagi, Yoshio Ikeda, Bunzo Matsuura, Kiyonori Takada, Yoichi Hiasa
Author information
JOURNAL OPEN ACCESS

2014 Volume 53 Issue 12 Pages 1343-1346

Details
Abstract
The present report describes a case of a patient with hepatitis B virus (HBV)-human immunodeficiency virus (HIV) co-infection who was treated with tenofovir disoproxil (TDF)-based highly active antiretroviral therapy (HAART) and who achieved HBs antigen (Ag)/antibody (Ab) seroconversion. An 18-year-old Japanese man with HIV and HBV co-infection presented to our hospital. His CD4 count was decreased, and TDF-based HARRT was started. At 30 months after initiation of therapy, HBsAg was not detected. At 36 months after initiation of therapy, HBsAb was detected. We conclude that TDF-based therapy is useful for the management of patients with HBV and HIV co-infection.
Content from these authors
© 2014 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top